Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 11-12/2014

01.06.2014 | original article

Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD

verfasst von: MD Dr. Andreas Scholler, MD Priv. Doz. Dr. Sibylla Richter-Mueksch, MD Dr. Birgit Weingessel, MD, MSc, MBA Univ. Doz. Dr. Pia-Veronika Vécsei-Marlovits

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Purpose

Intravitreal ranibizumab or bevacizumab are the most used drugs for treatment of neovascular age-related macular degeneration (nAMD). Repeated intravitreal injections represent an economic burden and may be associated with serious complications. The aim of this study is to evaluate the number of needed injections within 1 year of treatment.

Methods

55 patients over 50 years of age with nAMD and visual acuity (VA) between 20/40 and 20/320 were included. Scheduled visits and treatment were performed monthly for 1 year. After a loading dose of three intravitreal injections (either ranibizumab = group 1 or bevacizumab = group 2), an “as needed” regimen was performed. Primary endpoint was a difference in the injection frequencies of ranibizumab and bevacizumab. Secondary endpoints were best corrected visual acuity (BCVA) and central retinal thickness (CRT).

Results

Difference in number of injections was not significant (5.00 ± 1.67 (ranibizumab group) vs. 5.80 ± 2.28 (bevacizumab group), p = 0.084). Mean BCVA was 59.12 ± 16.64 letters after 12 months if patients received ranibizumab (p = 0.001) and 64.75 ± 17.03 letters if patients received bevacizumab (p = 0.037). There was no statistical significance between the two groups (p = 0.631). The mean CRT did not differ significantly between groups after 12 months (315.67 ± 65.86 µm for ranibizumab, 350.47 ± 102.84 µm for bevacizumab, p = 0.088).

Conclusion

There was no difference in number of treatment, BCVA and CRT after 1 year between ranibizumab and bevacizumab in patients with nAMD.
Literatur
1.
Zurück zum Zitat Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010; doi:10.1136/bmj.c2459. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010; doi:10.1136/bmj.c2459.
2.
Zurück zum Zitat Klein R, Klein BE, Jensen SC, Mares-Pearlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology. 1999;106:1056–65. PubMedCrossRef Klein R, Klein BE, Jensen SC, Mares-Pearlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology. 1999;106:1056–65. PubMedCrossRef
3.
Zurück zum Zitat Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Opthalmol. 2004;122:564–72. CrossRef Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Opthalmol. 2004;122:564–72. CrossRef
4.
Zurück zum Zitat Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. PubMedCrossRef Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411. PubMedCrossRef
5.
6.
Zurück zum Zitat Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–48. PubMedCrossRef Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–48. PubMedCrossRef
7.
Zurück zum Zitat Zampros I, Praidou A, Brazitikos P, Ekonomidis P, Androudi S. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol. 2012; doi:10.1155/2012/319728. Zampros I, Praidou A, Brazitikos P, Ekonomidis P, Androudi S. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol. 2012; doi:10.1155/2012/319728.
8.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. PubMedCrossRef Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. PubMedCrossRef
9.
Zurück zum Zitat Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83. PubMedCrossRef Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83. PubMedCrossRef
10.
Zurück zum Zitat Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71. PubMedCrossRef Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71. PubMedCrossRef
11.
Zurück zum Zitat Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. PubMedCentralPubMedCrossRef Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–83. PubMedCrossRef Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–83. PubMedCrossRef
13.
Zurück zum Zitat Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. PubMedCrossRef Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. PubMedCrossRef
14.
Zurück zum Zitat Feng XF, Constable IJ, McAllister IL, Isaacs T. Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration. Int J Ophthalmol. 2011; doi:10.3980/j.issn.2222-3959.2011.01.20. Feng XF, Constable IJ, McAllister IL, Isaacs T. Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration. Int J Ophthalmol. 2011; doi:10.3980/j.issn.2222-3959.2011.01.20.
Metadaten
Titel
Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD
verfasst von
MD Dr. Andreas Scholler
MD Priv. Doz. Dr. Sibylla Richter-Mueksch
MD Dr. Birgit Weingessel
MD, MSc, MBA Univ. Doz. Dr. Pia-Veronika Vécsei-Marlovits
Publikationsdatum
01.06.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0539-z